SAINT- PREX, Switzerland, August 31, 2011 (ots/PRNewswire) - Contact: Media enquiries: Orla Barnewell, Tonic Life Communications, Tel: +44 207 798 9915, orla.barnewell@toniclc.com; Helen Swift, Tonic Life Communications, Tel: +44 207 798 9924, helen.swift@toniclc.com; Patrick Gorman, Ferring Pharmaceuticals, Tel: ...
Saint-Prex, Switzerland (ots) - Results from a phase III pivotal study sub-analyses reported in European Urology show that prostate cancer patients who received Firmagon® (degarelix) in the study have a statistically significant greater probability of PSA (prostate-specific-antigen) recurrence-free survival ...
Amsterdam, The Netherlands (ots/PRNewswire) - - "Study Could Have Major Impact on the Decision-Making Process With Respect to Infertility Treatment" New data from an economic analysis presented today at this year's European Society of Human Reproduction and Embryology (ESHRE) congress showed that, within the parameters of the simulation model used, the in ...
New gonadotrophin-releasing hormone (GnRH) receptor antagonist demonstrates rapid, long-term suppression of testosterone Saint-Prex (ots) - Ferring Pharmaceuticals announced today that it has received marketing authorisation from the European Commission, for FIRMAGON® (degarelix), a new GnRH receptor antagonist ...
Saint Prex, Switzerland (ots/PRNewswire) - - New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-Term Suppression of Testosterone Ferring Pharmaceuticals received today notification that the Committee for Medicinal Products for Human Use (CHMP), part of the European ...
Barcelona (ots/PRNewswire) - The winners of the Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) are announced today at the European Society for Human Reproduction & Embryology Congress. The two winners of this new prize are the University Medical Centre Utrecht, The Netherlands and the Universitair Ziekenhuis (UZ) Brussel, Centre for Reproductive ...
21st Annual Meeting of the European Association of Urology (EAU), Paris, 5th - 8th April 2006 Treatment with degarelix results in fast, profound and sustained reductions in testosterone and prostate-specific antigen (PSA) levels without a testosterone surge Paris (ots) - Following the presentation today of the results of the Phase IIb programme with degarelix in prostate cancer, which are in line with previous ...
Copenhagen, Denmark (ots/PRNewswire) - - "Approximately five more pregnancies per 100 women treated" with MENOPUR compared to recombinant treatment New data presented today at the ESHRE (European Society of Human Reproduction and Embryology) congress supports the efficacy of MENOPUR (menotrophin), a highly purified, naturally-derived infertility treatment belonging to the class of drugs known as gonadotrophins, ...